Table 1. Demographic and clinical characteristics of the study subjects.
| Variable | PsC n = 23 # (%) or Mean (SD) |
PsA n = 13 # (%) or Mean (SD) |
Controls n = 18 # (%) or Mean (SD) |
P Value† |
|---|---|---|---|---|
| Males | 100% | 100% | 100% | n/a |
| Age (y) | 50.5 (14.4) | 52.3 (14.0) | 43.8 (12.1) | 0.18‡ |
| Age of Psoriasis | 29.9 (13.0) | 20.9 (9.9) | n/a | 0.04 |
| Age of PsA | n/a | 32.9 (8.9) | n/a | n/a |
| Psoriasis Duration (y) | 20.6 (15.1) | 31.4 (13.1) | n/a | 0.04 |
| PsA Duration (y) | n/a | 19.4 (14.2) | n/a | n/a |
| PASI* | 2.7 (0–23.8) | 1.6 (0–6.6) | n/a | 0.13 |
| Tender Joints | n/a | 1.3 (2.5) | n/a | n/a |
| Swollen Joints | n/a | 0.3 (0.9) | n/a | n/a |
| NSAIDs | 1 (4%) | 8 (62%) | n/a | <0.001 |
| DMARDs | 1 (4%) | 7 (54%) | n/a | 0.001 |
| Biologics | 4 (17%) | 7 (54%) | n/a | 0.02 |
† With the exception of age, p value reflects comparison of PsC vs PsA by Student’s t-test or Fisher’s Exact test.
‡ P value from ANOVA.
*Psoriasis Area and Severity Index; values indicate median PASI score (range); p value from Mann-Whitney U test.